Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (22437)	6/18/1998 2:25:00 AM
From: Torben Noerup Nielsen	Read Replies (5) \| Respond to of 32384

>I could see it being something serious like the manufacturing plant >not meeting FDA standards resulting in production of a questionable >product, to something fairly trivial like labeling alterations. Hopefully it's not the plant since LGND bought that too :-( I'm hoping for labeling alterations or something like that because of the 14-2 vote on the issue of allowing physicians to determine the dosage. I'm just baffled because of the overwhelming vote. And Bloomberg listing it as a market mover does not sound great in this case. Not unless there is some clarification on this issue. Thanks, Torben